LLY

890.37

+1.41%↑

JNJ

242.43

+0.9%↑

ABBV

212.4

+1.3%↑

NVS

150.25

+1.35%↑

MRK

117.53

-1.8%↓

LLY

890.37

+1.41%↑

JNJ

242.43

+0.9%↑

ABBV

212.4

+1.3%↑

NVS

150.25

+1.35%↑

MRK

117.53

-1.8%↓

LLY

890.37

+1.41%↑

JNJ

242.43

+0.9%↑

ABBV

212.4

+1.3%↑

NVS

150.25

+1.35%↑

MRK

117.53

-1.8%↓

LLY

890.37

+1.41%↑

JNJ

242.43

+0.9%↑

ABBV

212.4

+1.3%↑

NVS

150.25

+1.35%↑

MRK

117.53

-1.8%↓

LLY

890.37

+1.41%↑

JNJ

242.43

+0.9%↑

ABBV

212.4

+1.3%↑

NVS

150.25

+1.35%↑

MRK

117.53

-1.8%↓

Home・Akciju saraksts・Pulmatrix Inc

Pulmatrix Inc

Atvērts

1.22 -9.63

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.17

Max

1.35

Galvenie mērījumi
By Trading Economics
Ienākumi	-51K -928K
EPS	-0.24
Peļņas marža	-60,266.667
Darbinieki	2
EBITDA	-51K -928K

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-3.1M 8.3M
Iepriekšējā atvēršanas cena	10.85
Iepriekšējā slēgšanas cena	1.22

Pulmatrix Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 27. marts 17:33 UTC

Galvenie ziņu notikumi

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

2026. g. 27. marts 17:00 UTC

Galvenie ziņu notikumi

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

2026. g. 27. marts 16:03 UTC

Galvenie ziņu notikumi

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

2026. g. 29. marts 23:47 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Falls Amid Rising Inflation Fears -- Market Talk

2026. g. 29. marts 23:46 UTC

Tirgus saruna

Galvenie ziņu notikumi

Nikkei May Fall on Fears About Shortage of Petrochemical Products -- Market Talk

2026. g. 29. marts 23:35 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Rises on Supply-Disruption Concerns Spurred by Widening Mideast Conflict -- Market Talk

2026. g. 29. marts 23:23 UTC

Tirgus saruna

Australia's National Cabinet to Avoid Covid-Style Measures -- Market Talk

2026. g. 29. marts 22:34 UTC

Tirgus saruna

Macroeconomic Tailwind for Warehouse Dissipates -- Market Talk

2026. g. 29. marts 22:09 UTC

Tirgus saruna

Amplitude's Next Well "Effectively a Must-Win" for Growth Thesis -- Market Talk

2026. g. 29. marts 21:06 UTC

Tirgus saruna

Galvenie ziņu notikumi

Australia's Economy Could Already Be Contracting Amid Oil Shock -- Market Talk

2026. g. 29. marts 21:03 UTC

Tirgus saruna

Australia's Government Wants to Avoid Heavy Handed Oil Shock Response -- Market Talk

2026. g. 29. marts 21:01 UTC

Tirgus saruna

Galvenie ziņu notikumi

Australian National Cabinet Meeting to Focus on Oil Supply -- Market Talk

2026. g. 29. marts 09:30 UTC

Iegādes, apvienošanās, pārņemšana

Food Mega-Mergers Hardly Ever Work. Could McCormick-Unilever Be Different? -- Heard on the Street -- WSJ

2026. g. 28. marts 08:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 27. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 27. marts 19:16 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

2026. g. 27. marts 19:07 UTC

Tirgus saruna

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

2026. g. 27. marts 19:04 UTC

Tirgus saruna

Gold Rises But Can't Finish the Week Positive -- Market Talk

2026. g. 27. marts 19:03 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 27. marts 19:02 UTC

Tirgus saruna

Galvenie ziņu notikumi

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

2026. g. 27. marts 18:12 UTC

Tirgus saruna

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

2026. g. 27. marts 17:36 UTC

Galvenie ziņu notikumi

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

2026. g. 27. marts 17:34 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

2026. g. 27. marts 17:29 UTC

Tirgus saruna

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

2026. g. 27. marts 16:38 UTC

Tirgus saruna

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

2026. g. 27. marts 16:32 UTC

Tirgus saruna

Galvenie ziņu notikumi

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

2026. g. 27. marts 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 27. marts 15:43 UTC

Tirgus saruna

Galvenie ziņu notikumi

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

2026. g. 27. marts 15:25 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 27. marts 15:25 UTC

Tirgus saruna

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

Salīdzinājums

Cenas izmaiņa

Pulmatrix Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pulmatrix Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.